These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 37023499)

  • 21. The Use of Targeted Agents in the Treatment of Gynecologic Cancers.
    Bruce SF; Powell MA
    Curr Treat Options Oncol; 2022 Jan; 23(1):15-28. PubMed ID: 35167006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions.
    High P; Carmon KS
    Cancer Lett; 2023 Jun; 564():216191. PubMed ID: 37100113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
    Luu K; Chu A; Chang B
    J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
    Pan K; Gong J; Huynh K; Cristea M
    Target Oncol; 2019 Jun; 14(3):269-283. PubMed ID: 31069647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
    Nelson BE; Meric-Bernstam F
    Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
    Ma H; Sawas A
    Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
    Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
    Takakura T; Shimizu T; Yamamoto N
    Jpn J Clin Oncol; 2024 Aug; 54(8):837-846. PubMed ID: 38704241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Therapies in Gynecologic Cancer.
    Bejar FG; Oaknin A; Williamson C; Mayadev J; Peters PN; Secord AA; Wield AM; Coffman LG
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35594502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer.
    Sato S; Shoji T; Jo A; Otsuka H; Abe M; Tatsuki S; Chiba Y; Takatori E; Kaido Y; Nagasawa T; Kagabu M; Baba T
    Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New and Novel Therapies for Gynecologic Cancers.
    Richardson DL
    Semin Oncol Nurs; 2019 Apr; 35(2):217-219. PubMed ID: 30876683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.
    Malik S; Sikander M; Bell N; Zubieta D; Bell MC; Yallapu MM; Chauhan SC
    J Ovarian Res; 2024 Aug; 17(1):161. PubMed ID: 39118097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
    Prakash R; Subbiah V; Iyer SP
    Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.
    Ghose A; Lapitan P; Apte V; Ghosh A; Kandala A; Basu S; Parkes J; Shinde SD; Boussios S; Sharma A; Das P; Vasdev N; Rebuzzi SE; Ürün Y; Kanesvaran R; Maniam A; Banna GL
    Curr Oncol Rep; 2024 Jun; 26(6):633-646. PubMed ID: 38652426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
    Wolford JE; Ferrigni E; Margul D; Herzog TJ
    Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
    Singh D; Dheer D; Samykutty A; Shankar R
    J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The next generation of antibody drug conjugates.
    Mack F; Ritchie M; Sapra P
    Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update of antibody-drug conjugates for hematological malignancies.
    Sun W; Hu S; Wang X
    Curr Opin Oncol; 2024 Sep; 36(5):430-436. PubMed ID: 39007226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.